Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration.
Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. J Ocul Pharmacol Ther. 2012 Dec; 28(6):581-8.